How often did human graders agree with software designed to detect and quantify retinal fluid in wet AMD patients using a home OCT prototype? Moderator Sabin Dang, MD, is joined by panelists Lediana Goduni, MD, and Prethy Rao, MD, MPH, to examine how reliable such software was in a prospective observational study. After the break, the group speculates how these new data may affect retina doctors' comfort with home OCT and asks what is the minimum viable image quality required to trust home OCT imaging.  

How often did human graders agree with software designed to detect and quantify retinal fluid in wet AMD patients using a home OCT prototype? Moderator Sabin Dang, MD, is joined by panelists Lediana Goduni, MD, and Prethy Rao, MD, MPH, to examine how reliable such software was in a prospective observational study. After the break, the group speculates how these new data may affect retina doctors' comfort with home OCT and asks what is the minimum viable image quality required to trust home OCT imaging.

New Retina Radio Journal Club: Is Software on Home OCT as Good as Human Graders?

Were fluid-free visits correlated with outcomes in the HAWK/HARRIER studies? Moderator Katherine Talcott, MD, and panelists Kyle Kovacs, MD, and Rebecca Soares, MD, MPH, summarize data from a study examining this question, review what it means to be "free of fluid," and discuss how these data fit into the overall conversation about fluid toleration in wet AMD. 

Were fluid-free visits correlated with outcomes in the HAWK/HARRIER studies? Moderator Katherine Talcott, MD, and panelists Kyle Kovacs, MD, and Rebecca Soares, MD, MPH, summarize data from a study examining this question, review what it means to be "free of fluid," and discuss how these data fit into the overall conversation about fluid toleration in wet AMD.

New Retina Radio Journal Club:  Wet AMD: Fluid-free Visits' Association with Anatomic and Visual Outcomes

Is a solution to extending duration with aflibercept (Eylea, Regeneron) in DME patients an 8-mg dose rather than the typical 2-mg dose? Diana Do, MD, joined us to review data from the PHOTON study, which assessed the safety and efficacy of high-dose aflibercept in DME patients. And we hear from Jennifer Lim, MD, who summarized data on extending treatment intervals in the phase 3 YOSEMITE and RHINE studies. Could a significant number of DME patients make it to 12—or even 16—weeks before needing another faricimab (Vabysmo, Genentech/Roche) dose? 

Is a solution to extending duration with aflibercept (Eylea, Regeneron) in DME patients an 8-mg dose rather than the typical 2-mg dose? Diana Do, MD, joined us to review data from the PHOTON study, which assessed the safety and efficacy of high-dose aflibercept in DME patients. And we hear from Jennifer Lim, MD, who summarized data on extending treatment intervals in the phase 3 YOSEMITE and RHINE studies. Could a significant number of DME patients make it to 12—or even 16—weeks before needing another faricimab (Vabysmo, Genentech/Roche) dose?

New Retina Radio ARVO Coverage: DME Update: 8-mg Aflibercept data and Faricimab TAE in Phase 3

How are doctors using faricimab (Vabysmo, Genentech/Roche) in real-world settings? The IRIS Registry has a few answers. We sat down with Durga Borkar, MD, MMCi, to hear what researchers in the FARETINA-AMD study group found regarding dynamics related to faricimab’s use in wet AMD patients since its approval in January of last year.  We also interviewed Varun Chaudhary, MD, to learn specifically about faricimab treat-and-extend regimens in wet AMD patients who were enrolled in TENAYA and LUCERNE. How many patients achieved treatment intervals of 12 or 16 weeks? 

How are doctors using faricimab (Vabysmo, Genentech/Roche) in real-world settings? The IRIS Registry has a few answers. We sat down with Durga Borkar, MD, MMCi, to hear what researchers in the FARETINA-AMD study group found regarding dynamics related to faricimab’s use in wet AMD patients since its approval in January of last year.  We also interviewed Varun Chaudhary, MD, to learn specifically about faricimab treat-and-extend regimens in wet AMD patients who were enrolled in TENAYA and LUCERNE. How many patients achieved treatment intervals of 12 or 16 weeks?

New Retina Radio ARVO Coverage: Faricimab in Wet AMD: Real-world and Phase 3 Data

After years of failed clinical trials, we finally have an approved therapy for geographic atrophy, and more are hopefully on the way. Allen C. Ho, MD, and Robert L. Avery, MD, sit down with Eleonora M. Lad, MD, PhD; Jeffrey S. Heier, MD; and Dilsher Dhoot, MD, to discuss the introduction of geographic atrophy therapies into the retina clinic.

After years of failed clinical trials, we finally have an approved therapy for geographic atrophy, and more are hopefully on the way. Allen C. Ho, MD, and Robert L. Avery, MD, sit down with Eleonora M. Lad, MD, PhD; Jeffrey S. Heier, MD; and Dilsher Dhoot, MD, to discuss the introduction of geographic atrophy therapies into the retina clinic.

Treating GA In Your Clinic

What did an analysis of the Korean National Health Insurance Service database reveal about the link between age-related macular degeneration and depression risk? Moderator Sabin Dang, MD, is joined by panelists Lediana Goduni, MD, and Prethy Rao, MD, MPH, to summarize the study's findings. After the break, the discussion turns to whether depression screening should (or could) occur in retinal clinics, and how optimistic framing of a diagnosis may make a difference in the lives of patients. 

What did an analysis of the Korean National Health Insurance Service database reveal about the link between age-related macular degeneration and depression risk? Moderator Sabin Dang, MD, is joined by panelists Lediana Goduni, MD, and Prethy Rao, MD, MPH, to summarize the study's findings. After the break, the discussion turns to whether depression screening should (or could) occur in retinal clinics, and how optimistic framing of a diagnosis may make a difference in the lives of patients.

New Retina Radio Journal Club: AMD and Depression Risk

What does an analysis of the Japan-Retinal Detachment Registry reveal about the relationship between duration of macular detachment and visual prognosis? Moderator Priya Vakharia, MD, invites panelists Sruthi Arepalli, MD, and Vaidehi Dedania, MD, to explore the design and findings of a recent paper by Miyake et al on this topic. After the break, they discuss the clinical and medico-legal implications of the paper’s findings. 

What does an analysis of the Japan-Retinal Detachment Registry reveal about the relationship between duration of macular detachment and visual prognosis? Moderator Priya Vakharia, MD, invites panelists Sruthi Arepalli, MD, and Vaidehi Dedania, MD, to explore the design and findings of a recent paper by Miyake et al on this topic. After the break, they discuss the clinical and medico-legal implications of the paper’s findings.

New Retina Radio Journal Club: Duration of Macular Detachment and Final Visual Prognosis 

Cynthia A. Toth, MD, and Amani A. Fawzi, MD, sit down with experts Philip J. Rosenfeld, MD, PhD; SriniVas Sadda, MD; and Nadia K. Waheed, MD, MPH, to discuss the value of OCT angiography in the retina clinic. From assessing macular neovascularization to tracking treatment effect in patients with plaque choroidal retinopathies, this imaging modality can augment current tools—and even replace them, at times. Hear their pearls, tips, and tricks for integrating OCT angiography into your clinical routine.  

Cynthia A. Toth, MD, and Amani A. Fawzi, MD, sit down with experts Philip J. Rosenfeld, MD, PhD; SriniVas Sadda, MD; and Nadia K. Waheed, MD, MPH, to discuss the value of OCT angiography in the retina clinic. From assessing macular neovascularization to tracking treatment effect in patients with plaque choroidal retinopathies, this imaging modality can augment current tools—and even replace them, at times. Hear their pearls, tips, and tricks for integrating OCT angiography into your clinical routine.

The Utility of OCTA in the Clinic

The FDA approval of pegcetacoplan (Syfovre, Apellis Pharmaceuticals) is a historic moment for the field of retina, finally providing a treatment option for patients with geographic atrophy. Allen C. Ho, MD, and Robert L. Avery, MD, share their initial reactions to the approval and discuss the potential effect on patient care and clinical practice. 

The FDA approval of pegcetacoplan (Syfovre, Apellis Pharmaceuticals) is a historic moment for the field of retina, finally providing a treatment option for patients with geographic atrophy. Allen C. Ho, MD, and Robert L. Avery, MD, share their initial reactions to the approval and discuss the potential effect on patient care and clinical practice.

The Era of Geographic Atrophy Treatment Begins

Diversity and inclusion in medical practice is essential, and while retina specialists always have their patients’ and colleagues’ best interests at heart, sometimes that message can get lost in translation, especially when it comes to LGBTQ+ sensitivities. Vivienne S. Hau, MD, PhD, and Basil K. Williams Jr, MD, sat down with four experts—Jessica Weinstein, MD; Roberto Diaz-Rohena, MD; Steven Sanislo, MD; and Brandon Johnson, MD—to discuss ways to foster workplace diversity and inclusion for LGBTQ+ patients and physicians.

Diversity and inclusion in medical practice is essential, and while retina specialists always have their patients’ and colleagues’ best interests at heart, sometimes that message can get lost in translation, especially when it comes to LGBTQ+ sensitivities. Vivienne S. Hau, MD, PhD, and Basil K. Williams Jr, MD, sat down with four experts—Jessica Weinstein, MD; Roberto Diaz-Rohena, MD; Steven Sanislo, MD; and Brandon Johnson, MD—to discuss ways to foster workplace diversity and inclusion for LGBTQ+ patients and physicians.

Inclusion Pearls and Pitfalls For Retina Specialists

New Retina Radio is a place to hear stories about retina that are told nowhere else.

Awesome podcast! Very relevant for retina surgeons. John Kitchens is a master interviewer and moderator.

NRR rocks!

New Retina Radio by Eyetube

Many young retina specialists have always known retina as an anti-VEGF world. But how did this happen? John D. Pitcher III, MD, joins Scott and Ranna in studio to deliver the first part of the tale of anti-VEGF in retina, taking the story back to the 1970s to tell the story of the discovery of VEGF, the creation of pegaptanib, and the struggles that early anti-VEGF encountered in retina. There are a lot of guests for this one, but the major players for this episode are Tony Adamis, MD; Bob Avery, MD; Jeff Heier, MD; and Kirk Packo, MD. This editorially independent podcast is supported with advertising.

Many young retina specialists have always known retina as an anti-VEGF world. But how did this happen? John D. Pitcher III, MD, joins Scott and Ranna in studio to deliver the first part of the tale of anti-VEGF in retina, taking the story back to the 1970s to tell the story of the discovery of VEGF, the creation of pegaptanib, and the struggles that early anti-VEGF encountered in retina. There are a lot of guests for this one, but the major players for this episode are Tony Adamis, MD; Bob Avery, MD; Jeff Heier, MD; and Kirk Packo, MD. This editorially independent podcast is supported with advertising.

Anti-VEGF, A Biography: Part 1

New Retina Radio continues its biography of anti-VEGF. John D. Pitcher III, MD, picks up the story where we left off: in a world where pegaptanib was the only intravitreal injection approved for treating wet AMD. But a deep dive into the literature and a few calculations on the back of a napkin are about to change retina practice forever. Guests in this episode include Bob Avery, MD; Dave Brown, MD; Anne Fung, MD; Jeffrey Heier, MD; Andrew Moshfeghi, MD, MBA; Kirk Packo, MD; and Philip Rosenfeld, MD, PhD. This editorially independent podcast is supported with advertising.

New Retina Radio continues its biography of anti-VEGF. John D. Pitcher III, MD, picks up the story where we left off: in a world where pegaptanib was the only intravitreal injection approved for treating wet AMD. But a deep dive into the literature and a few calculations on the back of a napkin are about to change retina practice forever. Guests in this episode include Bob Avery, MD; Dave Brown, MD; Anne Fung, MD; Jeffrey Heier, MD; Andrew Moshfeghi, MD, MBA; Kirk Packo, MD; and Philip Rosenfeld, MD, PhD. This editorially independent podcast is supported with advertising.

Anti-VEGF, A Biography: Part 2

This story started in the early days of VEGF's isolation in the 1970s and brought us to the discovery of ranibizumab and bevacizumab in the mid 2000s. The data revealed at the ASRS meeting in 2005 would change retina forever-and usher in a new competitor with a chance to disrupt the landscape yet again.Don't miss the final episode of this fascinating and important story told by those that lived it. We're bringing back some of the voices you've heard before, and some new ones, too. John D. Pitcher III, MD, invites Bob Avery, MD; David Brown, MD; Jeffrey Heier, MD; Nancy Holekamp, MD; Kirk Packo, MD; Phillip Rosenfeld, MD, PhD; and Bob Vitti, MD, to tell the latest chapter of anti-VEGF's biography.This editorially independent podcast is supported with advertising.

This story started in the early days of VEGF's isolation in the 1970s and brought us to the discovery of ranibizumab and bevacizumab in the mid 2000s. The data revealed at the ASRS meeting in 2005 would change retina forever-and usher in a new competitor with a chance to disrupt the landscape yet again. Don't miss the final episode of this fascinating and important story told by those that lived it. We're bringing back some of the voices you've heard before, and some new ones, too. John D. Pitcher III, MD, invites Bob Avery, MD; David Brown, MD; Jeffrey Heier, MD; Nancy Holekamp, MD; Kirk Packo, MD; Phillip Rosenfeld, MD, PhD; and Bob Vitti, MD, to tell the latest chapter of anti-VEGF's biography. This editorially independent podcast is supported with advertising.

Anti-VEGF, A Biography: Part 3

All retina specialists have an MD; not all retina specialists have another postgraduate degree. In this episode of New Retina Radio, we examine how and why those degrees were obtained by retina specialists-and if they were even worth the time. Featuring Derek Kunimoto, MD, JD; Paul Hahn, MD, PhD; David Almeida, MD, PhD, MBA; and Scott Walter, MD, MS. This podcast is editorially independent.

All retina specialists have an MD; not all retina specialists have another postgraduate degree. In this episode of New Retina Radio, we examine how and why those degrees were obtained by retina specialists-and if they were even worth the time. Featuring Derek Kunimoto, MD, JD; Paul Hahn, MD, PhD; David Almeida, MD, PhD, MBA; and Scott Walter, MD, MS. This podcast is editorially independent.

Alphabet Soup: PhD, MBA, JD, MS

Practicing retina in the developing world means facing frustrating, unexpected, and sometimes dangerous circumstances. Don D'Amico, MD, R.V. Paul Chan, MD, and Pravin Dugel, MD, share their stories of engaging medical communities from Tanzania to Armenia and Vietnam to Nepal. This podcast is editorially independent.

Practicing retina in the developing world means facing frustrating, unexpected, and sometimes dangerous circumstances. Don D'Amico, MD, R.V. Paul Chan, MD, and Pravin Dugel, MD, share their stories of engaging medical communities from Tanzania to Armenia and Vietnam to Nepal. This podcast is editorially independent.

Beyond the Walls of ORs and Borders of Nations

Hawks have more than one fovea and a cornea that changes shape to sharpen focus on prey. Who knew? Well, one retina doctor did. James C. Major Jr, MD, PhD, joins us for an episode to review his early contributions to animal imaging. But the story is bigger than that. Dr. Major's journey illustrates that a marriage between two passions-in his case, the blossoming world of optical coherence tomography in the early 2000s and an ornithological hobby-can send a retina doctor down uncharted paths of scientific discovery. This podcast is editorially independent.

Hawks have more than one fovea and a cornea that changes shape to sharpen focus on prey. Who knew? Well, one retina doctor did. James C. Major Jr, MD, PhD, joins us for an episode to review his early contributions to animal imaging. But the story is bigger than that. Dr. Major's journey illustrates that a marriage between two passions-in his case, the blossoming world of optical coherence tomography in the early 2000s and an ornithological hobby-can send a retina doctor down uncharted paths of scientific discovery. This podcast is editorially independent.

Retina Is for the Birds

Finding a partner for your retina practice can be a lot like dating-you need to find someone whose values align with your values, who enhances your best qualities, and who doesn't make you pull your hair out. In this episode, New Retina Radio goes retro-think The Dating Game but (slightly) less corny. Featuring Geeta Lalwani, MD, and Charlie Mango, MD. This podcast is editorially independent.

Finding a partner for your retina practice can be a lot like dating-you need to find someone whose values align with your values, who enhances your best qualities, and who doesn't make you pull your hair out. In this episode, New Retina Radio goes retro-think The Dating Game but (slightly) less corny. Featuring Geeta Lalwani, MD, and Charlie Mango, MD. This podcast is editorially independent.

The Dating Game

The best podcast episodes of the most interesting stories and things. From skyping someone while they're in space, to tracking down and meeting a telephone scammer in person, to the story of a Galapagos. These episodes will keep you and all your friends entertained and captivated for hours. Learn something new in every episode! Add episodes you're interested into your queue below!

Best Episodes: Interesting Stories & Things

The best podcast episodes on non-current politics. Covering topics such as universal basic income, democracy, poverty & justice and more. For anyone interested in learning more about politics that affect that world, not just now, but in the longer term. Add episodes you're interested into your queue below!